World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
88
Citations
40234
World Ranking
1143
National Ranking
605

Medicine

D-Index
88
Citations
40234
World Ranking
12942
National Ranking
6615

Merlin L. Robb publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Merlin L. Robb sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 509 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Merlin L. Robb D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Merlin L. Robb sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 88 D-Index — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Merlin L. Robb is affiliated with the Walter Reed Army Institute of Research in the United States. Their research predominantly centers on infectious diseases, immunology, and microbiology, with particular emphasis on HIV research and treatment.

The main fields of study covered in their work include:

  • Medicine
  • Immunology and Microbiology

Specific subfields of study extend to:

  • Infectious Diseases
  • Virology
  • Immunology
  • Epidemiology
  • Molecular Biology

Key topics addressed in their publications include:

  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • HIV, Drug Use, Sexual Risk
  • HIV/AIDS drug development and treatment
  • HIV-related health complications and treatments

Merlin L. Robb has contributed to several recent papers, among them:

  • "Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19", 2021, published in the New England Journal of Medicine
  • "Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S", 2022, New England Journal of Medicine
  • "Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models", 2020, New England Journal of Medicine
  • "Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection", 2020, Science Translational Medicine
  • "Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication", 2021, Nature Immunology

Their frequent coauthors include:

  • Nelson L. Michael
  • Leigh Anne Eller
  • Trevor A. Crowell
  • Sandhya Vasan
  • Julie A. Ake

Merlin L. Robb's work is often published in venues such as:

  • PLoS Pathogens
  • bioRxiv (Cold Spring Harbor Laboratory)
  • PLoS ONE
  • UNC Libraries
  • Journal of Clinical Investigation

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

    Supachai Rerks-Ngarm;Punnee Pitisuttithum;Sorachai Nitayaphan;Jaranit Kaewkungwal

  • Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.

    Jerald Sadoff;Glenda Gray;An Vandebosch;Vicky Cárdenas

  • Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

    Barton F. Haynes;Peter B. Gilbert;M. Juliana McElrath;Susan Zolla-Pazner

  • Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

    John R. Mascola;Mark G. Lewis;Gabriela Stiegler;Dawn Harris

  • Human skin Langerhans cells are targets of dengue virus infection.

    Shuenn-Jue L. Wu;Geraldine Grouard-Vogel;Wellington Sun;John R. Mascola

  • Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys

    James B. Whitney;Alison L. Hill;Srisowmya Sanisetty;Pablo Penaloza-MacMaster

  • Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

    Dan H. Barouch;Dan H. Barouch;Jinyan Liu;Hualin Li;Lori F. Maxfield

  • Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

    Morgane Rolland;Paul T. Edlefsen;Brendan B. Larsen;Sodsai Tovanabutra

  • Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.

    Ann R Falsey;Magdalena E Sobieszczyk;Ian Hirsch;Stephanie Sproule

  • Effect of Human Immunodeficiency Virus Type 1 (HIV-1) Subtype on Disease Progression in Persons from Rakai, Uganda, with Incident HIV-1 Infection

    Noah Kiwanuka;Oliver Laeyendecker;Oliver Laeyendecker;Merlin Robb;Godfrey Kigozi

  • Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

    Unknown

  • Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys

    Dan H. Barouch;Dan H. Barouch;Kathryn E. Stephenson;Erica N. Borducchi;Kaitlin Smith

  • Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

    David C. Montefiori;Chitraporn Karnasuta;Ying Huang;Hasan Ahmed

  • International Seroepidemiology of Adenovirus Serotypes 5, 26, 35, and 48 in Pediatric and Adult Populations

    Dan H. Barouch;Dan H. Barouch;Sandra V. Kik;Gerrit J. Weverling;Rebecca Dilan

  • Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

    Dan H Barouch;Dan H Barouch;Frank L Tomaka;Frank Wegmann;Daniel J Stieh

  • Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand

    Merlin L Robb;Leigh A Eller;Hannah Kibuuka;Kathleen Rono

  • Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.

    Donn J. Colby;Lydie Trautmann;Lydie Trautmann;Suteeraporn Pinyakorn;Suteeraporn Pinyakorn;Louise Leyre

  • Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

    Kayvon Modjarrad;Christine C. Roberts;Kristin T. Mills;Amy R. Castellano

  • COMPASS identifies T-cell subsets correlated with clinical outcomes

    Lin Lin;Greg Finak;Kevin Ushey;Chetan Seshadri

  • Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys

    Erica N. Borducchi;Crystal Cabral;Kathryn E. Stephenson;Jinyan Liu

  • Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

    Merlin L Robb;Supachai Rerks-Ngarm;Sorachai Nitayaphan;Punnee Pitisuttithum

Frequent Co-Authors

Nelson L. Michael
Nelson L. Michael Walter Reed Army Institute of Research
Jerome H. Kim
Jerome H. Kim Walter Reed Army Institute of Research
Sorachai Nitayaphan
Sorachai Nitayaphan Armed Forces Research Institute of Medical Science
Jintanat Ananworanich
Jintanat Ananworanich Moderna Therapeutics (United States)
Deborah L. Birx
Deborah L. Birx Centers for Disease Control and Prevention
Morgane Rolland
Morgane Rolland Henry M. Jackson Foundation
Punnee Pitisuttithum
Punnee Pitisuttithum Mahidol University
Dan H. Barouch
Dan H. Barouch Harvard Medical School
Peter B. Gilbert
Peter B. Gilbert Fred Hutchinson Cancer Research Center
Georgia D. Tomaras
Georgia D. Tomaras Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in advancing their career in immunology-related healthcare fields, exploring degrees such as the Doctor of Nursing Practice (DNP) can be highly beneficial. One pathway is through specialized nursing programs like psychiatric mental health nurse practitioner degrees. Students can find the top pmhnp programs that offer excellent clinical placement rates, ensuring hands-on experience crucial for professional growth.

Affordability is a key consideration for many students. The availability of cheapest online pmhnp programs makes it easier to enter this career path without excessive financial burdens, opening doors for a wider range of aspiring healthcare professionals.

Understanding the financial outcomes is also important. According to data on doctor of nursing practice salary, DNP holders often enjoy competitive compensation, reflecting the advanced skills and responsibilities in this role.

Additionally, career flexibility allows many nurses to specialize further. For example, transitioning from family nurse practitioner roles to acute care is a common step, and guidance on how to make this move is available in resources such as fnp to acute care np. This kind of career progression can align well with the dynamic needs of immunology and related healthcare sectors.

Best Scientists Citing Merlin L. Robb

Trending Scientists

Recently Published Articles